Results 1 to 10 of about 77,763 (258)
Infectious retinitis associated with JAK inhibitors: the ongoing duality of JAK inhibitors [PDF]
International Journal of Retina and VitreousPurpose To discuss the recent evidence that Janus kinase (JAK) inhibitors can cause viral retinitis. Methods A commentary on the case report in this issue and a review of cases in the literature.
Jose S. Pulido +3 more
doaj +5 more sources
JAK Inhibitors in Psoriatic Disease
Clinical, Cosmetic and Investigational Dermatology, 2023 Matteo Megna,1 Luca Potestio,1 Angelo Ruggiero,1 Sara Cacciapuoti,1 Francesco Maione,2 Marco Tasso,3 Francesco Caso,3,* Luisa Costa3,* 1Section of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples,
Luisa Costa +2 more
exaly +6 more sources
Immunological Medicine, 2023 Among various tyrosine kinases, a family of Janus kinases (JAK) has been elucidated as key players in signal transduction from vital cytokine receptors, such as interleukins and interferons.
Hideto Kameda
doaj +3 more sources
JAK inhibitors in rheumatology
Immunological Medicine, 2023 Janus kinase inhibitors (JAKis) are a group of drugs with a different mechanism of action from biologics and are most rapidly uptaken in the rheumatology field.
Kunihiro Yamaoka, Kenji Oku
doaj +3 more sources
Journal for ImmunoTherapy of Cancer, 2022 During SARS-CoV-2 infection, the innate immune response can be inhibited or delayed, and the subsequent persistent viral replication can induce emergency signals that may culminate in a cytokine storm contributing to the severe evolution of COVID-19. Cytokines are key regulators of the immune response and virus clearance, and, as such, are linked to ...
Gabriel Levy +3 more
doaj +4 more sources
New insights into IFN-γ in rheumatoid arthritis: role in the era of JAK inhibitors
Immunological Medicine, 2020 The treatment of rheumatoid arthritis (RA) is now entering a new era, the era of Janus kinase (JAK) inhibitors. JAK inhibitors target multiple cytokines including IL-6 and exhibit a beneficial treatment effect in patients with RA and inadequate response ...
Masaru Kato
exaly +2 more sources
JAK Be Nimble: Reviewing the Development of JAK Inhibitors and JAK Inhibitor Combinations for Special Populations of Patients with Myelofibrosis [PDF]
Journal of Immunotherapy and Precision Oncology, 2021 Myelofibrosis (MF) is a myeloproliferative neoplasm hallmarked by uncontrolled blood counts, constitutional symptoms, extramedullary hematopoiesis, and an increased risk of developing acute myeloid leukemia.
Andrew T. Kuykendall, Rami S. Komrokji
doaj +4 more sources
JAK inhibitors in the management of extra-intestinal manifestations in inflammatory bowel disease [PDF]
Therapeutic Advances in GastroenterologyExtra-intestinal manifestations (EIMs) commonly occur in patients with inflammatory bowel diseases (IBD) and contribute significantly to morbidity and reduced quality of life. Their management remains challenging.
Fotios S. Fousekis +4 more
doaj +2 more sources
Indian Journal of Dermatology, Venereology and Leprology, 2023 The Janus kinase (JAK)-signal transducer and activator of transcription (STAT) pathway is a key regulatory signaling system for cellular proliferation, differentiation, and apoptosis. In addition, JAK signaling pathway plays critical roles in orchestrating immune response through its interactions with the cytokine receptors and the transcriptions ...
Siba P, Raychaudhuri +1 more
openaire +2 more sources
JAK Inhibitors in Rheumatoid Arthritis
European Medical Journal Allergy & Immunology, 2022 JAK inhibitors (JAKi) are targeted, small-molecule, disease-modifying therapies that are the newest class of treatments to emerge for the management of rheumatoid arthritis (RA) and the first oral disease-modifying anti-rheumatic drugs (DMARD) to ...
Kathryn Biddle +2 more
doaj +1 more source